Obesity & Metabolism
All products sold in this category are intended exclusively for research, laboratory analysis and analytical applications. Under no circumstances are they intended for human consumption, nor for medical, therapeutic, diagnostic, cosmetic, veterinary or any other application not related to research.
The statements and products presented on this website have not been evaluated by any regulatory authority. They are not intended to diagnose, treat, cure or prevent any disease or medical condition.
None of the products referenced on this website constitutes a medical product and may not be marketed, resold or used as such.
By placing an order, the buyer acknowledges that they assume full responsibility for compliance with all applicable local, national and international laws and regulations relating to the purchase, handling and use of materials intended for research. Selmi Swiss declines all liability in the event of misuse of its products, unintended consequences resulting from inappropriate use, or any breach by the buyer of the regulations in force.
Any order placed for these products on this website implies acceptance and understanding of these conditions.
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
CJC-1295 without DAC
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
Ipamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A clean GH surge with no side effects associated with cortisol or prolactin.
- Increased lean muscle mass and fat loss.
- Improved sleep quality and recovery.
- Regulation of intestinal motility, with application in ileus.
- Ideal for long-term use due to its selectivity profile.
- Reference for use in combination with CJC-1295 without DAC.
L-carnitine
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved fat oxidation and energy production.
- Improved exercise performance and reduced fatigue.
- Cardiovascular health: reduces markers of atherosclerosis.
- Improving Insulin Sensitivity in Research on Type 2 Diabetes Mellitus.
- Male Fertility: Sperm Motility and Improved Sperm Count.
- Neuroprotective, with a preference for the acetyl-L-carnitine form for the CNS.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
New
SLU-PP-332
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Exercise mimicry: metabolic adaptations without physical exertion.
- Improved mitochondrial density and respiratory capacity.
- Increased endurance and fat oxidation.
- Potential effects on muscle aging and atrophy.
- Prevention of metabolic disease without the need for exercise.
- Synergy with AICAR for a comprehensive simulation of exercise.
New
Tesamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH's natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
